Tumor Associated Cell Articles & Analysis
5 news found
The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma. ...
Singaporean medical technology specialist X-ZELL has appointed Sebastian Grote as Managing Director, effective from 1 March 2022. Grote previously served as Head of Marketing & Strategy at X-ZELL and has been with the company since 2017, when it first came out of stealth mode to raise a two-part, USD 5.6m seed round. Since then, he initiated a series of global brand-building campaigns that ...
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...
X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide. Previously exclusive to X-ZELL, the patented system is part of the company’s single-cell diagnostics platform, which is capable of isolating and visualising individual atypical cells from a small 10mL blood sample. According to X-ZELL’s Head of Engineering ...
Award-winning Singaporean start-up, X-ZELL, has announced the formation of a new, interdisciplinary Imaging Technology division. The announcement comes on the back of a new collaboration agreement with Finnish Artificial Intelligence (AI) specialist, Aiforia Technologies, and is part of the ongoing digitisation of X-ZELL’s patented rare cell detection technology. X-ZELL’s modular ...